Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has announced significant enhancements to its AI-Immunology platform’s EvaxMHC component, which now demonstrates superior precision in predicting vaccine targets. These advancements, presented at the ISMB conference, improve the design of personalized and precision vaccines, particularly for cancer and infectious diseases. Evaxion’s upgraded deep-learning framework within EvaxMHC has shown promising results in preclinical studies and is being utilized in the ongoing Phase 2 trial of Evaxion’s leading cancer vaccine candidate.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
